Closed System Transfer Device Market: Market Size & Forecast 2026

CSTDs are used primarily in hospital pharmacies, oncology clinics, and compounding centers to protect healthcare workers from occupational exposure to hazardous drugs. The market is closely tied to oncology care delivery, with demand scaling alongside chemotherapy volumes and the rollout of stricter handling standards. Devices are evaluated against performance protocols developed by bodies such as the U.S. National Institute for Occupational Safety and Health (NIOSH), which assess vapor containment and leak prevention.

• •Estimated global market value of USD 1.49 billion in 2025
• •Projected CAGR of approximately 10.3% through the forecast period
• •Standards such as USP <800> and FDA product code ONB govern device classification and adoption

Regulatory pressure is the single most influential growth driver, with USP <800> mandating engineered controls for hazardous drug handling across U.S. healthcare settings. Rising global cancer prevalence and the corresponding expansion of chemotherapy services continue to increase the addressable patient base. Heightened awareness of occupational health risks among pharmacists, nurses, and compounding staff is accelerating institutional adoption.

• •USP <800> compliance is driving widespread hospital adoption in the United States
• •Growing global cancer burden increases chemotherapy compounding volumes
• •Heightened focus on occupational safety among healthcare workers supports demand

The market is typically segmented by device type, including syringe-mounted adapters, vial access devices, and bag/bottle spike systems, as well as by end-user setting such as hospitals, oncology centers, and home infusion services. North America represents the largest regional market due to early regulatory implementation and high cancer treatment rates, while Europe is experiencing accelerated uptake following the publication of USP-equivalent handling guidance. The Asia-Pacific region is emerging as the fastest-growing segment as healthcare infrastructure modernizes.

• •Major device categories include syringe adaptors, vial access devices, and bag or bottle spike systems
• •North America leads the market, supported by USP <800> adoption and advanced oncology infrastructure
• •Asia-Pacific is positioned as the fastest-growing regional segment

What are the recent trends and outlook?

Recent innovation efforts are focused on developing automatic pressure-relief mechanisms and high-efficiency transfer components designed to reduce operator workload while maintaining containment integrity. Manufacturers are investing in devices compatible with a broader range of hazardous drug formulations, including emerging biopharmaceuticals and antibody-drug conjugates. Looking ahead, the market is expected to benefit from the international diffusion of USP <800>-style handling standards and continued institutional investment in oncology pharmacy infrastructure.

• •Automatic pressure-relief and high-efficiency transfer designs represent the leading technological frontier
• •Compatibility with novel oncology drug classes is expanding the device applicability
• •International harmonization of hazardous drug handling standards will support sustained global growth